Quanterix Corporation (QTRX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Masoud Toloue Ph.D. | President, CEO & Director | 1.44M | -- | 1981 |
| Dr. David R. Walt Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director | 47.25k | -- | 1953 |
| Mr. Daniel Pikora | Chief Operating Officer | -- | -- | 1976 |
| Dr. David C. Duffy Ph.D. | Senior VP of Research & Development and CTO | 299.05k | -- | 1971 |
| Ms. Alexandra Phillips | Senior VP & Chief Information Officer | -- | -- | -- |
| Ms. Laurie A. Churchill | Senior VP, General Counsel & Secretary | -- | -- | 1971 |
| Mr. Naren Bhat | Senior Vice President of Corporate Development & Strategy | -- | -- | -- |
| Ms. Erica Bell | Chief People Officer | -- | -- | 1973 |
| Dr. Mark T. Roskey Ph.D. | Senior Vice President of Strategic Partnerships | 495.03k | 845.13k | 1960 |
| Ms. Mary Ellen Cortizas | VP of Laboratory Services & CRO | -- | -- | -- |
Quanterix Corporation
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 441
Description
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Corporate Governance
Recent Events
- Apr 15, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Apr 12, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 04, 2024S-8: Offering RegistrationsSee Full Filing
- Feb 29, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 27, 20248-K: Corporate Changes & Voting MattersSee Full Filing